CARD11 is altered in 14.29% of diffuse large B-cell lymphoma patients with CARD11 Mutation present in 13.13% of all diffuse large B-cell lymphoma patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 6.45% of mycosis fungoides patients with CARD11 Mutation present in 6.45% of all mycosis fungoides patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and mycosis fungoides as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 5.41% of anaplastic large cell lymphoma patients with CARD11 Mutation present in 5.41% of all anaplastic large cell lymphoma patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 3.37% of cancer patients with CARD11 Mutation present in 2.73% of all cancer patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 2.6% of head and neck squamous cell carcinoma patients with CARD11 Mutation present in 2.5% of all head and neck squamous cell carcinoma patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 2.29% of cervical carcinoma patients with CARD11 Mutation present in 1.78% of all cervical carcinoma patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 2.65% of peripheral T-cell lymphoma, not otherwise specified patients with CARD11 Mutation present in 1.77% of all peripheral T-cell lymphoma, not otherwise specified patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 is altered in 1.35% of angioimmunoblastic T-cell lymphoma patients with CARD11 Mutation present in 1.35% of all angioimmunoblastic T-cell lymphoma patients [4].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for adult T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and adult T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for enteropathy-associated T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and enteropathy-associated T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for follicular T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and follicular T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for hepatosplenic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and hepatosplenic T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for monomorphic epitheliotropic intestinal T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and monomorphic epitheliotropic intestinal T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for nasal type extranodal NK/T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for sezary syndrome, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and sezary syndrome as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CARD11 Mutation is an inclusion criterion in 1 clinical trial for subcutaneous panniculitis-like T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 Mutation and subcutaneous panniculitis-like T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].